Moderna (MRNA) is a publicly traded Healthcare sector company. As of July 5, 2026, MRNA trades at $79.76 with a market cap of $31.65B and a P/E ratio of -9.79. MRNA moved +10.14% today. Year to date, MRNA is +162.28%; over the trailing twelve months it is +163.41%. Its 52-week range spans $22.28 to $81.40. Analyst consensus is neutral with an average price target of $45.42. Rallies surfaces MRNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for MRNA combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $79.76 |
| Market Cap | $31.65B |
| P/E Ratio | -9.79 |
| EPS | $-8.15 |
| Dividend Yield | 0.00% |
| 52-Week High | $81.40 |
| 52-Week Low | $22.28 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.23B |
| Net Income | $-3.19B |
| Gross Margin | 22.11% |
16 analysts cover MRNA: 0 strong buy, 1 buy, 13 hold, 2 sell, 0 strong sell. Consensus rating is neutral. Average price target: $45.42.